ライフサイエンスコーパス: glycosylated hemoglobin

1 as well as two of the six studies measuring glycosylated hemoglobin).

2 inhibitors [AGIs], and insulin adjusted for glycosylated hemoglobin).

3 001) between serum protein argpyrimidine and glycosylated hemoglobin.

4 values, as well as significant decreases in glycosylated hemoglobin.

5 tis is associated with a slight elevation in glycosylated hemoglobin.

6 cerides, SBP, DBP, BMI, waist/hip ratio, and glycosylated hemoglobin.

7 esterol, total to HDL cholesterol ratio, and glycosylated hemoglobin].

8 lic blood pressure (-9.37 mm Hg; p < 0.001), glycosylated hemoglobin (-0.92%; p < 0.001), and smoking

9 table plaque and healed infarct had elevated glycosylated hemoglobin (10.2 +/- 5.0% versus 6.4 +/- 0.

10 n, mean diabetes duration 29 years, and mean glycosylated hemoglobin 7.9%).

11 f fasting serum glucose, insulin, C-peptide, glycosylated hemoglobin A (HbA1c), and Homeostasis Model

12 The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blo

13 The importance of glycosylated hemoglobin A1c (A1c) control as part of com

14 with fluorinated compounds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole bloo

15 ation of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown.

16 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent

17 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71

18 Subjects were categorized with glycosylated hemoglobin A1c and fundus photography.

19 plasma glucose by 0.69 mmol/L [1.32; 0.07], glycosylated hemoglobin A1C by 0.37% [0.54; 0.20], body

20 gender, body mass index, diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

21 Fasting plasma glucose, glycosylated hemoglobin A1c, BMI, micro/macrovascular co

22 tegerin, osteocalcin, osteopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were a

23 adjusting for duration of diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage r

24 assessment-estimated insulin resistance, and glycosylated hemoglobin A1c.

25 herapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not

26 tively and significantly related to maternal glycosylated hemoglobin and plasma glucose.

27 yperglycemic at 26 weeks of age had elevated glycosylated hemoglobin and sciatic nerve sorbitol level

28 six subjects with normal fasting glucose and glycosylated hemoglobin and seven overtly diabetic subje

29 and duration of diabetes, level of control (glycosylated hemoglobin), and demographic data were reco

30 f diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER.

31 justment for age, sex, duration of diabetes, glycosylated hemoglobin, and blood pressure.

32 Weights, blood sugar, glycosylated hemoglobin, and detailed ERGs were recorded

33 Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excreti

34 s in a 24-site US AMI registry (2005-08) had glycosylated hemoglobin assessed at a core laboratory, w

35 p diabetes (P = 5.7 x 10(-10)) and had lower glycosylated hemoglobin (beta = -0.14 SD units, P = 1.1

36 terol, high-density lipoprotein cholesterol, glycosylated hemoglobin, cigarette smoking) in addition

37 Total cholesterol (TC), HDL cholesterol, glycosylated hemoglobin, cigarette smoking, and hyperten

38 Fasting plasma glucose and glycosylated hemoglobin concentrations returned to norma

39 Blood-glycosylated hemoglobin concentrations were not signific

40 ithout affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clear

41 The mean levels of glycosylated hemoglobin decreased by 1.0% in the 4 mg/d

42 total/high density lipoprotein cholesterol, glycosylated hemoglobin), diabetes mellitus, cardiovascu

43 adjusting for age, gender, body mass index, glycosylated hemoglobin, diabetes duration, systolic blo

44 subjects) displays elevated plasma glucose, glycosylated hemoglobin, diastolic blood pressure, and c

45 r decline was higher after age 35 yr or when glycosylated hemoglobin exceeded 9% but did not vary wit

46 aphic QTc interval for long QT syndrome, and glycosylated hemoglobin for maturity-onset diabetes of t

47 low-up, subjects who were in "poor" control (glycosylated hemoglobin (GHb) > or = 11%) at baseline we

48 han values in the WT mice; blood glucose and glycosylated hemoglobin (GHb) levels did not differ in t

49 nsive description of glycemic control (total glycosylated hemoglobin (GHb)) up to 4.5 years duration

50 yperglycemia ratio increment; p < 0.001) and glycosylated hemoglobin greater than or equal to 6.5% (4

51 cholesterol, multivessel CAD, diabetes with glycosylated hemoglobin >7%, and persistent angina were

52 e the variables baseline body mass index and glycosylated hemoglobin have missing values.

53 on quality was significantly associated with glycosylated hemoglobin (Hb A(1c)) levels.

54 strates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin (HbA(1c) ) in diabetes patients

55 primary outcome (simultaneous control with a glycosylated hemoglobin (HbA(1c)) <7.0%, blood pressure

56 y disease; however, the relationship between glycosylated hemoglobin (HbA(1c)) as a marker of chronic

57 aptoglobin (Hp) polymorphism rs#72294371 and glycosylated hemoglobin (HbA(1c)) on risk of coronary he

58 al glucose tolerance test); 2) with baseline glycosylated hemoglobin (HbA1) less than 9%; and 3) who

59 8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA1) level of 10.0% (1.9%).

60 current smokers (grade A), and patients with glycosylated hemoglobin (HbA1C) >/= 6.5% (grade B).

61 ncluded low-density lipoprotein </= 70mg/dl, glycosylated hemoglobin (HbA1c) </= 6.5%, and systolic b

62 4, OR10-14 years = 2.07, OR15+years = 3.99), glycosylated hemoglobin (HbA1c) (OR6.5-6.9% = 1.33, OR7-

63 er of their selection): age, creatinine, and glycosylated hemoglobin (HbA1c) (standardized beta-age:

64 designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in

65 abetes control was assessed by percentage of glycosylated hemoglobin (HbA1c) and divided into three c

66 Glycosylated hemoglobin (HbA1c) and fasting blood glucos

67 n terms of adjusted r-square, in forecasting glycosylated hemoglobin (HbA1c) and fasting plasma gluco

68 Mean glycosylated hemoglobin (HbA1c) and mean DM duration wer

69 the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA1c) at 6- and 12-month follo

70 Measurement of glycosylated hemoglobin (HbA1c) is a gold standard proce

71 f 72 individuals were grouped based on their glycosylated hemoglobin (HbA1c) levels and clinical para

72 The duration of DM and the glycosylated hemoglobin (HbA1c) levels of the patients i

73 diators did not correlate with age, race, or glycosylated hemoglobin (HbA1C) levels.

74 comes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels.

75 risk of those outcomes at both high and low glycosylated hemoglobin (HbA1c) levels.

76 nother agent in the 120 days after the index glycosylated hemoglobin (HbA1C) measurement.

77 Mental State Examination of 28.6 +/- 1.5, a glycosylated hemoglobin (HbA1C) of 5.88 +/- 0.74%, and a

78 Recently, glycosylated hemoglobin (HbA1c) of 6.5% or higher (>/= 4

79 Glycosylated hemoglobin (HbA1c) was assessed using a cha

80 between the prevalence of periodontitis and glycosylated hemoglobin (HbA1c) was verified in the biva

81 the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both gr

82 Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by

83 nder-the-curve glucose after glucose load or glycosylated hemoglobin (HbA1c), and measures of insulin

84 index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood urea nitrogen, se

85 Admission glycosylated hemoglobin (HbA1c), glucose levels, and com

86 rement of random blood glucose levels, serum glycosylated hemoglobin (HbA1c), serum porcine C peptide

87 short-term reduction in the concentration of glycosylated hemoglobin (HbA1c).

88 ood pressure (DBP), waist circumference, and glycosylated hemoglobin (HbA1c).

89 association between H. pylori and levels of glycosylated hemoglobin (HbA1c).

90 h type 2 diabetes and poor glycemic control (glycosylated hemoglobin [HbA1c] levels > or =8.0%) and p

91 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated hemoglobin [HbA1c] value, 7.4% [SD, 1.0%]),

92 hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA1c], 6.5%-8.5%) and were rec

93 factor changes (fasting blood glucose [FBG], glycosylated hemoglobin [HbA1c], systolic or diastolic b

94 s to these bacteria, and blood sugar levels (glycosylated hemoglobin, HbAlc) were studied before and

95 estimates for glycosylated hemoglobin (total glycosylated hemoglobin, hemoglobin A1, or hemoglobin A1

96 r increased extent of macular edema), higher glycosylated hemoglobin, history of diabetic neuropathy,

97 cholesterol levels, triglycerides, glucose, glycosylated hemoglobin, insulin resistance, and dual-en

98 sting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3

99 Glycosylated hemoglobin is an indicator of long-term gly

100 he purpose of this study was to determine if glycosylated hemoglobin is elevated in patients with per

101 luded age, gender, BP, body mass index, GFR, glycosylated hemoglobin, LDL cholesterol, HDL cholestero

102 y associated with mortality in patients with glycosylated hemoglobin less than 6.5% (odds ratio = 1.0

103 inuria of short duration, salutary levels of glycosylated hemoglobin (less than 8 percent), low systo

104 represented a 1-percentage point increase in glycosylated hemoglobin level (95% CI, 1.10 to 1.26) in

105 ssure (diabetic and nondiabetic patients) or glycosylated hemoglobin level (diabetic patients only).

106 hospitalization were longitudinally measured glycosylated hemoglobin level (rate ratio = 1.5 per 2% i

107 among patients with diabetes, only 28% had a glycosylated hemoglobin level measured.

108 of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin level of 7% or less [corrected].

109 ose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body m

110 during the open treatment phase (mean +/- SD glycosylated hemoglobin level reduction, -0.4% +/- 1.4%;

111 diabetes, chronic hyperglycemia (assessed by glycosylated hemoglobin level) is related to the develop

112 waist-to-hip ratio, physical activity index, glycosylated hemoglobin level, and other factors.

113 italization in the preceding 6 months, lower glycosylated hemoglobin level, and questionnaire respons

114 controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-pep

115 gnificantly correlated with blood glucose or glycosylated hemoglobin level.

116 sting glucose: 9.9 (2.5) mmol/dL, and HbA1c (glycosylated hemoglobin) level: 8.9% (1.2%).

117 Glycosylated hemoglobin levels and insulin doses were al

118 style, there was a significant difference in glycosylated hemoglobin levels between those who rated t

119 Glycosylated hemoglobin levels decreased during the open

120 Deaths and mean glycosylated hemoglobin levels did not differ between th

121 reatment are associated with improvements in glycosylated hemoglobin levels for at least 1 year.

122 ble to discontinue insulin therapy and their glycosylated hemoglobin levels improved.

123 Glycosylated hemoglobin levels remained significantly lo

124 Mean glycosylated hemoglobin levels were 5.2+/-0.9% (off ster

125 our postdextrose glucose concentrations, and glycosylated hemoglobin levels were available from 11 27

126 than for white girls in every age group, and glycosylated hemoglobin levels were highest for black an

127 reports from 1966 through June 1994 in which glycosylated hemoglobin levels were measured concurrentl

128 Post-treatment glycosylated hemoglobin levels were not different in the

129 ferent in the two groups, but follow-up mean glycosylated hemoglobin levels were significantly better

130 Glycosylated hemoglobin levels, fasting plasma glucose l

131 ts, emergency department visits, death rate, glycosylated hemoglobin levels, medications, and past me

132 tory; glycemic control was measured by using glycosylated hemoglobin levels.

133 mproved glucose tolerance and a reduction in glycosylated hemoglobin levels.

134 also associated in the CVRF-free group with glycosylated hemoglobin levels.

135 iabetic medication were further adjusted for glycosylated hemoglobin levels.

136 ch was assessed via serial determinations of glycosylated hemoglobin levels.

137 ssure, high-density lipoprotein cholesterol, glycosylated hemoglobin, lipoprotein(a) and fibrinogen l

138 osis factor-alpha, fasting glucose, insulin, glycosylated hemoglobin, low-density lipoprotein cholest

139 e <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin <5.7%, and total cholesterol <20

140 [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin <7%) in BARI 2D.

141 or pneumococcal vaccination to 88% for serum glycosylated hemoglobin measurement.

142 t, blood pressure, random serum glucose, and glycosylated hemoglobin measurements.

143 of diabetic retinopathy was associated with glycosylated hemoglobin (odds ratio [OR], 1.27; 95% CI,

144 sly unknown DM, defined by a core laboratory glycosylated hemoglobin of >/=6.5%.

145 ith type 1 or type 2 diabetes mellitus, with glycosylated hemoglobin of less than 12%, central area t

146 nor documentation of DM in the chart (median glycosylated hemoglobin of unrecognized patients, 6.7%;

147 to the previously established role for total glycosylated hemoglobin, other factors including height,

148 plasma glucose concentration, percentage of glycosylated hemoglobin, plasma insulin concentration, a

149 rs of progression to definite DSP were total glycosylated hemoglobin (relative risk (RR) for increase

150 ow-density lipid, high-density lipid, HbA1c (glycosylated hemoglobin), serum creatinine, eosinophils,

151 Glycosylated hemoglobin, serum glucose while fasting, se

152 and endorsed as an acceptable screen for DM, glycosylated hemoglobin testing should be considered for

153 Glucose tolerance, C-peptide, and glycosylated hemoglobin tests confirmed the restoration

154 Moreover, by measuring total glycosylated hemoglobin (TGH) in 997 pregnant women as a

155 rovascular disease; however, the relation of glycosylated hemoglobin to macrovascular disease is less

156 MI); lipid profile; and levels of glucose or glycosylated hemoglobin, to identify those with metaboli

157 Adjusted relative risk estimates for glycosylated hemoglobin (total glycosylated hemoglobin,

158 e incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabet

159 liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage p

160 ent glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up perio

161 ary albumin excretion rate and with the mean glycosylated hemoglobin value during the mean duration (

162 The absolute decrease in the glycosylated hemoglobin value was 1.9 percent (95 percen

163 we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated he

164 Poorly controlled diabetes was defined as glycosylated hemoglobin values > 8%.

165 Minimal differences in mean glycosylated hemoglobin values (HbAlc) were noticed befo

166 The adjusted mean glycosylated hemoglobin values decreased by 0.8 and 1.4

167 The mean glycosylated hemoglobin values have been dramatically re

168 ations during fasting and postprandially and glycosylated hemoglobin values were measured periodicall

169 nsulin-dependent (type 2) diabetes mellitus (glycosylated hemoglobin values, 8 to 12 percent; normal,

170 Glycosylated hemoglobin was only measured in patients wi

171 Glycosylated hemoglobin was used to estimate average glu

172 c model assessment of insulin resistance and glycosylated hemoglobin were measured from a fasting blo

173 Samples for plasma glucose and for glycosylated hemoglobin were obtained at 24-28 weeks' ge

174 Glycosylated hemoglobin, which was 10.4% pretreatment, d